Advancing Novel Therapeutic Solutions for Life-Threatening Fungal Infections
Amplyx Pharmaceuticals is developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune compromised patients.
Amplyx has raised $118.5 million in venture capital and secured more than $10 million in grants from the National Institutes of Health to support its drug discovery and development efforts.
Amplyx is advancing a novel small-molecule therapy, APX001, in clinical development. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive aspergillosis and invasive candidiasis planned for initiation in early 2018.
Ciara Kennedy, Ph.D. – President and CEO
Mike Hodges, M.D. – Chief Medical Officer
Karen Joy Shaw, Ph.D. – Chief Scientific Officer